Clincosm LogoSign in Get a demo

CEPHEUS: Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia

Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT00687492
Collaborator
(none)
8,000
Enrollment
59
Locations
7
Duration (Months)
135.6
Patients Per Site
19.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    8000 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
    Study Start Date :
    May 1, 2008
    Actual Primary Completion Date :
    Dec 1, 2008
    Actual Study Completion Date :
    Dec 1, 2008

    Outcome Measures

    Primary Outcome Measures

    1. The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country) [After collecting all Patient Record Form.]

    Secondary Outcome Measures

    1. The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets. [After collecting all Patient Record Form.]

    2. The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables. [After collecting all Patient Record Form.]

    3. The physician characteristics associated with the allocation of hypercholesterolemia treatment regime. [After collecting all Patient Record Form.]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • 2 or more risk factors (according to NCEP ATP III guideline)

    • Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

    Exclusion Criteria:

    • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).

    • Previous enrolment or randomisation of treatment in the present study.

    • Participation in a clinical study during the last 90 days.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research Site Hong Kong Hong Kong China
    2 Research Site Semarang Central Java Indonesia
    3 Research Site Jakarta DKI Jakarta Indonesia
    4 Research Site Sidoarjo East Java Indonesia
    5 Research Site Surabaya East Java Indonesia
    6 Research Site Medan North Sumatra Indonesia
    7 Research Site Bandung West Java Indonesia
    8 Research Site Cheon-an Chung-Cheong-nam-do Korea, Republic of
    9 Research Site Bu-cheon Gyeong-gi Korea, Republic of
    10 Research Site Bundang Gyeong-gi Korea, Republic of
    11 Research Site Gu-ri Gyeong-gi Korea, Republic of
    12 Research Site Il-san Gyeong-gi Korea, Republic of
    13 Research Site Su-won Gyeong-gi Korea, Republic of
    14 Research Site Ma-san Gyung-sang-nam-do Korea, Republic of
    15 Research Site Bu-san Korea, Republic of
    16 Research Site Dae-gu Korea, Republic of
    17 Research Site Dae-jeon Korea, Republic of
    18 Research Site Gwangju Korea, Republic of
    19 Research Site In-cheon Korea, Republic of
    20 Research Site Je-ju Korea, Republic of
    21 Research Site Seoul Korea, Republic of
    22 Research Site Ul-san Korea, Republic of
    23 Research Site Bangsar Kuala Lumpur Malaysia
    24 Research Site Kepong Kuala Lumpur Malaysia
    25 Research Site Puchong Kuala Lumpur Malaysia
    26 Research Site Setapak Kuala Lumpur Malaysia
    27 Research Site Ampang Selangor Malaysia
    28 Research Site Bandar Sunway Selangor Malaysia
    29 Research Site Batu Caves Selangor Malaysia
    30 Research Site Hulu Selangor Selangor Malaysia
    31 Research Site Klang Selangor Malaysia
    32 Research Site Petaling Jaya Selangor Malaysia
    33 Research Site Port Klang Selangor Malaysia
    34 Research Site Sekinchan Selangor Malaysia
    35 Research Site Seri Kembangan Selangor Malaysia
    36 Research Site Shah Alam Selangor Malaysia
    37 Research Site Subang Jaya Selangor Malaysia
    38 Research Site Subang Selangor Malaysia
    39 Research Site Sungai Buloh Selangor Malaysia
    40 Research Site Kuala Lumpur Malaysia
    41 Research Site Selangor Malaysia
    42 Research Site Lipa Batangas Philippines
    43 Research Site Baguio Benguet Philippines
    44 Research Site Davao Philippines
    45 Research Site Iloilo Philippines
    46 Research Site Manila Philippines
    47 Research Site Kaohsiung Taiwan
    48 Research Site Taichung Taiwan
    49 Research Site Tainan Taiwan
    50 Research Site Taipei Taiwan
    51 Research Site Taoyuan Taiwan
    52 Research Site Bangkoknoi Bangkok Thailand
    53 Research Site Dusit Bangkok Thailand
    54 Research Site Pathumwan Bangkok Thailand
    55 Research Site Ratchathewi Bangkok Thailand
    56 Research Site Muang ChiangMai Thailand
    57 Research Site Klongluang Pathumthani Thailand
    58 Research Site Hanoi Vietnam
    59 Research Site Hcmc Vietnam

    Sponsors and Collaborators

    • AstraZeneca

    Investigators

    • Principal Investigator: Park Jeong Euy, Sungkyunkwan University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00687492
    Other Study ID Numbers:
    • NIS-CAP-DUM-2008/1
    First Posted:
    May 30, 2008
    Last Update Posted:
    Dec 2, 2010
    Last Verified:
    Dec 1, 2010
    Keywords provided by , ,
    hypercholesterolemia
    NCEP ATP III guidelines
    survey
    Additional relevant MeSH terms:
    Hypercholesterolemia

    Study Results

    No Results Posted as of Dec 2, 2010